HLA genotypes and rubella vaccine immune response: additional evidence.
Recent population-based studies have demonstrated the genetic heritability of rubella vaccine response and assessed that the HLA system may explain about 20% of the inter-individual variance in humoral immune response to this vaccine. Our earlier studies compared HLA allelic associations with rubella vaccine-specific antibodies between two smaller cohorts of healthy Rochester, MN, children (346 and 396 subjects) after two doses of rubella-containing vaccine. This study found that specific HLA alleles were consistently associated with rubella-specific antibody titers (B*27:05, DPA1*02:01, and DPB1*04:01 alleles). The current study examined HLA associations in an independent larger cohort of 1012 healthy San Diego, CA, subjects (age 19-40 years) after rubella vaccine in order to replicate our previous findings in the Rochester subjects. Two HLA associations of comparable magnitudes were consistently observed between B*27:05 (median NT50 Rochester cohort 48.9, p=0.067; San Diego cohort 54.8, p=0.047) and DPB1*04:01 (median NT50 Rochester cohort 61.6, p<0.001; San Diego cohort 70.8, p=0.084) alleles and rubella virus-neutralizing antibody titers. Additional HLA alleles resulted in consistent effects on IL-6 production in both cohorts, but did not meet criteria for statistical significance. Our data suggest these HLA alleles play a role in rubella vaccine-induced immunity and provide the basis for future studies that may explain the mechanism(s) by which these HLA polymorphisms affect immune responses to rubella vaccine.
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA.
Inna G
IG
Ovsyannikova
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
V Shane
VS
Pankratz
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
Beth R
BR
Larrabee
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Robert M
RM
Jacobson
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: poland.gregory@mayo.edu.
Gregory A
GA
Poland
D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D005260:Female; D005838:Genotype; D015234:HLA-A Antigens / Q000235:genetics; D015796:HLA-B27 Antigen / Q000235:genetics*; D059868:HLA-DP beta-Chains / Q000235:genetics*; D006801:Humans; D056724:Immunity, Humoral; D008297:Male; D008875:Middle Aged; D012411:Rubella Vaccine / Q000627:therapeutic use*; D055815:Young Adult
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D015234:HLA-A Antigens; C506273:HLA-A*31:01 antigen; C464936:HLA-B*27:05 antigen; D015796:HLA-B27 Antigen; D059868:HLA-DP beta-Chains; C505113:HLA-DPB1*04:01 antigen; D012411:Rubella Vaccine
Cytokines; HLA antigens; Neutralizing antibodies; Rubella vaccine